Arcutis Biotherapeutics, Inc. (ARQT)
| Market Cap | 2.76B +58.3% |
| Revenue (ttm) | 376.07M +91.3% |
| Net Income | -16.14M |
| EPS | -0.13 |
| Shares Out | 124.03M |
| PE Ratio | n/a |
| Forward PE | 60.71 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,034,251 |
| Open | 22.92 |
| Previous Close | 22.21 |
| Day's Range | 22.12 - 23.46 |
| 52-Week Range | 11.86 - 31.77 |
| Beta | 1.74 |
| Analysts | Strong Buy |
| Price Target | 34.00 (+52.54%) |
| Earnings Date | May 5, 2026 |
About ARQT
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company’s lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Bio... [Read more]
Financial Performance
In 2025, Arcutis Biotherapeutics's revenue was $376.07 million, an increase of 91.34% compared to the previous year's $196.54 million. Losses were -$16.14 million, -88.47% less than in 2024.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for ARQT stock is "Strong Buy." The 12-month stock price target is $34.0, which is an increase of 52.54% from the latest price.
News
Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting
WESTLAKE VILLAGE, Calif., and DENVER, March 18, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful in...
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric Dermatology
ZORYVE cream 0.05% was safe and well-tolerated, with efficacy that was maintained and improved over time up to 56 weeks of treatment Children ages 2-5 who achieved disease clearance and who switched t...
Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth
WESTLAKE VILLAGE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in...
Baron Health Care Fund Q4 2025 Recent Activity
During the quarter, Baron Health Care Fund added seven new positions and exited ten positions, bringing the number of positions in the Fund to 43. We bought shares of Arcutis Biotherapeutics, Inc., a ...
Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis
Phase 1a/1b, first-in-human study to evaluate safety and tolerability for investigational ARQ-234 in healthy volunteers and adults with moderate to severe atopic dermatitis ARQ-234 is a potent fusion-...
Arcutis Management to Present at TD Cowen's 46th Annual Health Care Conference
WESTLAKE VILLAGE, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in i...
Arcutis Earnings: Zoryve Dominance And Pipeline Catalysts Drive The Bull Case
Arcutis Biotherapeutics delivered a strong Q4 2025, with $127.5M in revenue (+84% YoY) and a GAAP EPS beat, driven by Zoryve's rapid adoption. ARQT is transitioning from a launch-stage biotech to a pr...
Arcutis Biotherapeutics, Inc. (ARQT) Q4 2025 Earnings Call Transcript
Arcutis Biotherapeutics, Inc. (ARQT) Q4 2025 Earnings Call Transcript
Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Q4 2025 net product revenue for ZORYVE® (roflumilast) was $127.5 million, an 84% increase compared to Q4 2024, and a 29% increase compared to Q3 2025 Full year 2025 net product revenue for ZORYVE was ...
Professional Golfer Max Homa Joins Arcutis' Free to Be Me Campaign, Urging Individuals with Seborrheic Dermatitis to Tee Up a Conversation with Their Healthcare Provider About Long-Term Treatments
Max Homa shares his journey with seborrheic dermatitis to encourage others to take control of their symptoms ZORYVE® (roflumilast) foam 0.3% is a once-daily, steroid-free, leave-in topical foam unique...
Arcutis After The Double: Hypergrowth Peaks, Compounding Remains
Arcutis Biotherapeutics shifts to Hold after a 100% rally, as much of the initial de-risked growth thesis has played out. ZORYVE approvals and revenue growth have driven a fair rerating, but forward e...
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WESTLAKE VILLAGE, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in ...
Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis
WESTLAKE VILLAGE, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in ...
Arcutis Biotherapeutics, Inc. Announces Termination of Promotion Agreement with Kowa
WESTLAKE VILLAGE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in ...
Arcutis to Report Fourth Quarter and Full Year 2025 Financial Results and Present at Upcoming Investor Conference
WESTLAKE VILLAGE, Calif., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in i...
Nationwide Survey Underscores Concerns with Use of Topical Steroids and Need for Long-Term Treatment Strategies Facing the 46 Million Americans with Chronic Inflammatory Skin Conditions
Nearly 9 in 10 adults and parents of children with plaque psoriasis, atopic dermatitis, and seborrheic dermatitis being treated with topical steroids are concerned about side effects Nearly 8 in 10 ad...
Arcutis Highlights 2026 Strategic Priorities and Anticipated Milestones
Continued strong growth of ZORYVE® (roflumilast) in 2026 with full-year net product sales guidance of $455–$470 million Advancement of ZORYVE indication-expansion strategy beginning with ongoing Phase...
Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri
Arcutis today announced that Amit Munshi has been appointed to its BOD, and announced the retirement of founder and Board member Bhaskar Chaudhuri, PhD.
Arcutis Biotherapeutics: The Earnings Inflection Has Arrived
Arcutis Biotherapeutics has transitioned to profitability, driven by Zoryve's strong sales growth and market acceptance. Management projects Zoryve peak sales of $2.6B–$3.5B, far above Wall Street's $...
FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5
FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5
PGIM Jennison Health Sciences Fund Q3 2025 Contributors And Detractors
The S&P 1500 Health Care Index advanced 4.0% in the third quarter, underperforming the S&P 500, which gained 8.1%. Stock selection within biotechnology and health care providers & services, along with...
Arcutis Completes Enrollment in INTEGUMENT-INFANT Phase 2 Study Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis
Investigational ZORYVE cream 0.05% was formulated for the delicate skin of infants and young children with mild to moderate atopic dermatitis Topline results anticipated in Q1 2026 The U.S. FDA approv...
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE® (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical Dermatology
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE® (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis
Mother-Daughter Duo, Tori Spelling and Stella McDermott, Partner With Arcutis Biotherapeutics in the Free to Be Me Campaign, Urging People With Inflammatory Skin Conditions to Speak With Their Healthcare Provider About Long-Term Treatments
Tori Spelling shares her and her family's journey with eczema and seborrheic dermatitis to encourage others to take control of their skin health ZORYVE® (roflumilast) is the #1 prescribed branded topi...
Arcutis Launches ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5
Once-daily, effective, safe, and well-tolerated ZORYVE cream 0.05% now commercially available for children as young as age 2 ZORYVE cream 0.05% provides rapid clearance of atopic dermatitis ZORYVE can...